Generation Bio (GBIO) Current Deferred Revenue (2023 - 2025)
Historic Current Deferred Revenue for Generation Bio (GBIO) over the last 3 years, with Q3 2025 value amounting to $149000.0.
- Generation Bio's Current Deferred Revenue fell 9870.57% to $149000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $149000.0, marking a year-over-year decrease of 9870.57%. This contributed to the annual value of $10.6 million for FY2024, which is 1808.96% down from last year.
- Per Generation Bio's latest filing, its Current Deferred Revenue stood at $149000.0 for Q3 2025, which was down 9870.57% from $1.5 million recorded in Q2 2025.
- Generation Bio's Current Deferred Revenue's 5-year high stood at $13.6 million during Q2 2024, with a 5-year trough of $149000.0 in Q3 2025.
- In the last 3 years, Generation Bio's Current Deferred Revenue had a median value of $10.6 million in 2024 and averaged $8.3 million.
- As far as peak fluctuations go, Generation Bio's Current Deferred Revenue soared by 12534.77% in 2024, and later crashed by 9870.57% in 2025.
- Quarter analysis of 3 years shows Generation Bio's Current Deferred Revenue stood at $12.9 million in 2023, then decreased by 18.09% to $10.6 million in 2024, then tumbled by 98.59% to $149000.0 in 2025.
- Its Current Deferred Revenue was $149000.0 in Q3 2025, compared to $1.5 million in Q2 2025 and $2.1 million in Q1 2025.